冠昊生物
(300238)
| 流通市值：44.73亿 | | | 总市值：44.73亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 141,434,634.79 | 140,951,077.71 | 121,854,759.37 | 106,780,152.15 |
| 应收票据及应收账款 | 47,970,229.8 | 63,022,682.9 | 57,946,787.32 | 59,545,736.88 |
| 应收账款 | 47,970,229.8 | 63,022,682.9 | 57,946,787.32 | 59,545,736.88 |
| 预付款项 | 7,589,380.81 | 2,579,608.81 | 9,668,348.23 | 2,075,119.15 |
| 其他应收款合计 | 1,046,683.54 | 1,626,040.81 | 2,300,314.45 | 2,205,177.66 |
| 存货 | 83,499,364.16 | 76,133,035.57 | 73,838,054.27 | 78,459,032.6 |
| 其他流动资产 | 19,192,061.1 | 20,250,649 | 16,823,995.27 | 16,724,518.68 |
| 流动资产合计 | 300,732,354.2 | 304,563,094.8 | 282,432,258.91 | 265,789,737.12 |
| 非流动资产: | | | | |
| 长期股权投资 | 48,490.18 | 48,490.18 | 48,490.18 | 4,489,812.53 |
| 其他权益工具投资 | 18,000,000 | 18,000,000 | 18,000,000 | 18,000,000 |
| 投资性房地产 | 8,235,378.13 | 8,346,662.17 | 8,457,946.21 | 8,569,230.25 |
| 固定资产 | 311,609,662.27 | 313,650,627.59 | 316,579,858.34 | 319,541,816.39 |
| 在建工程 | 3,287,470.7 | 2,743,282.31 | 2,542,364.88 | 2,542,364.88 |
| 使用权资产 | 6,640,750.14 | 7,881,403.32 | 9,138,937.54 | 10,383,342.13 |
| 无形资产 | 73,783,553.48 | 75,786,505.15 | 77,827,893 | 72,701,685.89 |
| 开发支出 | 29,786,158.81 | 28,714,360.37 | 27,522,291.54 | 26,619,457.5 |
| 长期待摊费用 | 2,865,049.74 | 3,098,448.34 | 3,057,356.36 | 3,260,108.72 |
| 递延所得税资产 | 18,116,512.48 | 18,199,164.92 | 18,342,913.9 | 18,420,720.17 |
| 其他非流动资产 | 1,401,553.05 | 1,736,528.93 | 292,500 | 4,081,555.83 |
| 非流动资产合计 | 473,774,578.98 | 478,205,473.28 | 481,810,551.95 | 488,610,094.29 |
| 资产总计 | 774,506,933.18 | 782,768,568.08 | 764,242,810.86 | 754,399,831.41 |
| 流动负债: | | | | |
| 短期借款 | 11,006,535.99 | 19,013,199.88 | 20,013,819.32 | 20,014,583.21 |
| 应付票据及应付账款 | 13,967,590.19 | 12,401,243.31 | 13,265,856.82 | 35,649,866.21 |
| 应付账款 | 13,967,590.19 | 12,401,243.31 | 13,265,856.82 | 35,649,866.21 |
| 预收款项 | 827,670.29 | 908,738.12 | 978,836.12 | 720,874.08 |
| 合同负债 | 29,350,335.12 | 28,725,715.96 | 27,372,908.72 | 28,762,770.74 |
| 应付职工薪酬 | 14,253,921.45 | 16,190,351.28 | 9,454,046.06 | 18,356,099.97 |
| 应交税费 | 8,529,870.43 | 7,790,089.91 | 12,164,972.99 | 7,982,583.69 |
| 其他应付款合计 | 66,977,905.17 | 71,932,624.56 | 55,167,189.53 | 58,625,557.85 |
| 一年内到期的非流动负债 | 5,092,026.42 | 5,594,173.59 | 5,858,032.52 | 5,720,129.93 |
| 其他流动负债 | 2,291,843.69 | 2,258,627.52 | 1,679,719.48 | 2,158,496.09 |
| 流动负债合计 | 152,297,698.75 | 164,814,764.13 | 145,955,381.56 | 177,990,961.77 |
| 非流动负债: | | | | |
| 长期借款 | 100,950,000 | 99,000,000 | 99,000,000 | 76,000,000 |
| 租赁负债 | 3,148,612.92 | 4,015,804.21 | 5,169,909.38 | 6,615,111.89 |
| 递延收益 | 18,515,471.91 | 18,819,949.44 | 19,124,426.97 | 19,428,904.5 |
| 递延所得税负债 | 6,102,261.42 | 6,198,777.59 | 6,679,251.81 | 6,772,950.03 |
| 非流动负债合计 | 128,716,346.25 | 128,034,531.24 | 129,973,588.16 | 108,816,966.42 |
| 负债合计 | 281,014,045 | 292,849,295.37 | 275,928,969.72 | 286,807,928.19 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 265,155,701 | 265,155,701 | 265,155,701 | 265,155,701 |
| 资本公积 | 594,420,828.47 | 594,420,828.47 | 594,541,559.87 | 594,541,559.87 |
| 其他综合收益 | -46,458,339.5 | -46,464,437.81 | -46,405,497.26 | -46,388,548.35 |
| 盈余公积 | 50,643,420.67 | 50,643,420.67 | 50,643,420.67 | 50,643,420.67 |
| 未分配利润 | -291,640,283.13 | -297,954,685.58 | -306,727,931.28 | -321,594,027.95 |
| 归属于母公司股东权益合计 | 572,121,327.51 | 565,800,826.75 | 557,207,253 | 542,358,105.24 |
| 少数股东权益 | -78,628,439.33 | -75,881,554.04 | -68,893,411.86 | -74,766,202.02 |
| 股东权益合计 | 493,492,888.18 | 489,919,272.71 | 488,313,841.14 | 467,591,903.22 |
| 负债和股东权益合计 | 774,506,933.18 | 782,768,568.08 | 764,242,810.86 | 754,399,831.41 |
| 公告日期 | 2025-10-29 | 2025-08-28 | 2025-04-23 | 2025-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |